Laboratorio de Toxicología Molecular, Centro de Investigación Aplicada en Ambiente y Salud, Coordinación para la Innovación y Aplicación de la Ciencia y la Tecnología, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México; Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México.
Laboratorio de Toxicología Molecular, Centro de Investigación Aplicada en Ambiente y Salud, Coordinación para la Innovación y Aplicación de la Ciencia y la Tecnología, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México; Facultad de Enfermería, Universidad Autónoma de Zacatecas, Zacatecas, Zacatecas, México.
Arch Med Res. 2019 Jul;50(5):285-294. doi: 10.1016/j.arcmed.2019.08.009. Epub 2019 Oct 5.
BACKGROUND/AIM: Cardiovascular diseases (CVD) are the most important cause of mortality globally. Nevertheless, the World Health Organization have declared that a precise and quick recognition of susceptible individuals to develop CVD is imperative to combat those illnesses. Additionally, developing countries need affordable alternatives to effectively prognosticate cardiovascular events. Therefore, the objective of this study was to assess well-established clinical prognostic markers in Mexican women to identify affordable, specific, and useful tools to predict cardiovascular events.
A cross-sectional study was performed including 340 healthy women. Anthropometric and clinical measurements were acquired from all enrolled individuals. Also, a blood sample of each participant women was obtained to complete biochemical analyses (triglycerides, glucose, total cholesterol, LDL cholesterol, and HDL cholesterol), and serum asymmetric dimethylarginine (ADMA), and adipocyte-fatty acid binding protein (FABP4) determinations. Finally, with anthropometric, clinical and biochemical determinations, atherogenic indices (Framingham risk score, Castelli's risk index, and atherogenic index of plasma) were estimated.
A mean value of 6.5 ± 7.2 was detected for the Framingham risk score, 3.7 ± 1.3 for Castelli's risk index, and 0.12 ± 0.22 for the atherogenic index of plasma (AIP). Circulating mean ADMA and FABP4 levels found in assessed women were 0.68 ± 0.34 mmol/L and 20.3 ± 16.6 ng/mL, respectively. Furthermore, strong positive relationships (p <0.05) between AIP and serum FABP4 and ADMA concentrations were detected after adjustment by traditional CVD risk factors.
In conclusion, AIP could be recommended as a potential biomarker in the early diagnosis of CVD events in developing countries.
背景/目的：心血管疾病（CVD）是全球最重要的死亡原因。然而，世界卫生组织已经宣布，精确和快速识别易患 CVD 的个体对于对抗这些疾病至关重要。此外，发展中国家需要负担得起的替代方案来有效地预测心血管事件。因此，本研究的目的是评估在墨西哥女性中确立的临床预后标志物，以确定负担得起、具体和有用的工具来预测心血管事件。
进行了一项横断面研究，纳入了 340 名健康女性。从所有入组的个体中获取了人体测量和临床测量值。此外，还从每位研究对象女性中采集了一份血样，以完成生化分析（甘油三酯、葡萄糖、总胆固醇、LDL 胆固醇和 HDL 胆固醇）以及血清不对称二甲基精氨酸（ADMA）和脂肪细胞脂肪酸结合蛋白（FABP4）的测定。最后，根据人体测量、临床和生化测定，估计了致动脉粥样硬化指数（弗雷明汉风险评分、卡斯特利风险指数和血浆致动脉粥样硬化指数）。
发现弗雷明汉风险评分的平均值为 6.5±7.2，卡斯特利风险指数的平均值为 3.7±1.3，血浆致动脉粥样硬化指数（AIP）的平均值为 0.12±0.22。评估女性的循环平均 ADMA 和 FABP4 水平分别为 0.68±0.34mmol/L 和 20.3±16.6ng/mL。此外，在调整传统 CVD 风险因素后，发现 AIP 与血清 FABP4 和 ADMA 浓度之间存在强烈的正相关（p<0.05）。
总之，AIP 可作为发展中国家 CVD 事件早期诊断的潜在生物标志物。
